Olaparib Tablets Maintenance Monotherapy Ovarian Cancer patients after Complete or Partial Response to Platinum Chemotherapy

Trial Identifier: D0816C00016
Sponsor: AstraZeneca
NCTID:: NCT03534453
Start Date: May 2018
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030
CN Wuhan, CN, 430030